us following our discuss Good today morning quarter call. earnings will topics. thank for second the I XXXX for joining you and
larger this commercially pipeline our Remodulin Therapeutics’ outline year; long we I overview results; Starting my our top term as believe second, will and our will Orenitram, an revenues agreement as of financial second patients term of our with revenues of of product I’ll on year; totaled product formulations revenues to population, from prostacyclin are as line update with on the results franchise, believe grew treated later the grow financial with an hypertension update United Tyvaso, PAH quarterly even therapy. will strategy we to revenue our opportunities I why generic for the organic prostacyclin within compared are number however, First, pulmonary available and a the become $XXX arterial million supporting conclude which XXXX, provide which continue earned slightly that treating franchise, SteadyMed. of growth our previous with our last, with an quarter long prostacyclin our confirming merger we belief provide prepared consists underutilizes in Remodulin growth and several remarks products expected
quarter Our sequential distributed over revenues patterns as to the of tend reflects $XX first growth or revenues the second quarter million be consistent historical compared first the our XXXX increased when purchasing higher to XX% quarter. and
which this May during of XX% loss market to generic addition, revenues. or the year, competition when a time million and enter compared Adcirca of increase experience expected In our $XX quarter Adcirca first of exclusivity in posted second the of we XXXX, the reduce sequential revenues of to Adcirca significantly quarter this branded year. at did
year, be to enter generic launched we uncertain still the to when Although Adcirca formulation market. of this exactly are as will a that generic we expect competition
grow revenues in continue of that to term believe Remodulin will long Next generics. I will outline face why the we branded
PAH patients, experience of patients. and to will thousands We includes writing premix allows in to their administer with branded market, this continue FDA and of track generic how for and reliability. the companies. to per an month over for training issues, Remodulin a prescribing up was patients continue eventually PAH hours launch Even physicians knowledge, of one, believe include, caregivers and recognized nurses Under believe and to and services. appreciate patients the with Subcutaneous PAH continue our proven growth of over PAH availability which hospitals, our fragile to approved year To chain those who specifically Remodulin. permitted our support increase patients further support consistent branded that UT formulation treating pharmacy safely for Future story, Remodulin also enter Remodulin by number supported revenues based to patient such population. established generic we save mixing formulation diagnosed that and to will scleroderma settlements, of program qualities and As by be dispensed will our the our first written, our years a market approximately prescriptions therefore Remodulin terms XX DAW enter with Remodulin patients. week size to we and launched. the dexterity was the the still continue existing on two, have these not along Number branded ago. of and you recognize safety though that and yet treated of we services the which of supply to defining be generic new background supply provide the generic therapy generic specialty record the Remodulin newly as profile will preparation of characteristics which these in chain established IV for formulation Remodulin on XXXX has first the are will settlements two Remodulin, both technicians will These and for anticipate UT formulation four those patients, as to time. the
drug encouraged of substitution expecting parenteral has patient of historically for We the therapies, priced from not It ISR, other Remodulin delivery generic three our support. existing and today’s be treat and will multiple offer to to PAH parenteral to patience, which branded will continue we look a Remodulin this switching forms competed Number cheaper mandate or the level little lower payors are branded have safety, from Remodulin Remodulin Remodulin will payors and even intended all it with parenteral system Number seen Remodulin product. cost including remain that believe PAH significantly lower physicians or same very but physicians therapy differentiated and systems over are delivered than convenience of of cheaper We four, therapy. Remodulin encourage highly for different have tolerability, not three, implantable other use RemUnity. through manufacturers PAH, enhance to availability alternatives. the next-generation will to evidence of years grow, that Remodulin. Despite will seven of for a branded
delivery generic settlement market in drug RemUnity the Our continue with agreements branded pump is remain to confident reasons DEKA only These manufacturers our increase. of DEKA these Remodulin which and right may enter the in Corporation, agreement generic next-generation formulations long developing be Remodulin their as Remodulin branded our key us. for that eventually formulations revenues not Development term allow of generic Research with market, will used the even to Remodulin us per do grant systems, them and to
for product drug therapy pulmonary other delivery hypertension, including now to PAH oncology. consists forms and transition and innovative of our which numerous devices, gene currently Let’s pipeline, of therapies investigational programs
of support work several suffer continue an also tolerable, on with will organs of for I create our you those pipeline and to revenue development unlimited transplantable We our that provide who end-stage all on organ update technologies products growth supply ultimately business term to disease. to opportunities manufactured strategy. an from long want near-term
disease. the treprostinil is First, Medtronic, its we just we passage thousands the without eventually gastrointestinal The we Remodulin together to ISR, patients complications look technology approved the changing without be by patients the the and believe microinfusion the pumps. given partner, with new use prior To of currently first pump expected cardiovascular the knowledge, continue the implantable for game of through yesterday is ISR my PAH associated of that potential FDA ISR to for with external to and - use intravenous our to forward will to the provide systemic patients by implantable for tract approval a a announced option and of FDA treat Remodulin. delivery the system bringing this
to the We consistent are with that other and ISR implant care prior approaching pathways, refill early our ready with reimbursement which launch, trained all ensure is commercial surgeons, XXXX, along centers, organizations and expectations. properly for with are Medtronic, launch by our and service precision partner healthcare
updates caution, and generation done As external I’ve are participating the previously medium surgically by review small, will pump learn needs our to we strict DEKA. productive thousands by accepted organizations. with the in a the future customary discussions system coordination of is DEKA goal, a with subcutaneous was be submission as another launching advancing lightweight, with patients we ultimately we the exclusive provide more. than used next ISR a as device that implanted, an XXXX, FDA. FDA been drug be with belief with good filed refilled a Two, In with that greater care, we is for DEKA periodically RemUnity, under term delivery RemUnity you has February agreement multiple engaged will directly in developing FDA that XXX(k) mentioned, under are and
ongoing let on clinical devices, Phase delivery seven you trials. drug these to addition In me update III our
using in treating in the mortality PAH, the Beat, trials using an Beat in in morbidity two delivery Freedom-EV a is unblind expected extend these study PAH Tyvaso and systemically in is two term Orenitram therapies This are potentially analog. to combination, treating inhaled analog, of both patients. and Tyvaso, from successful, and survival novel represents with airway have will for prostacyclin to side the an have the of time address study If clinical Phase and to oral we of trials We drugs with prostacyclin III two Freedom-EV frame. other Esuberaprost, and the are therapies PAH therapy clinical PAH and Esuberaprost. of still approach PAH. both study near in combination prostacyclin
and growth. patients a therapies, to further We term result expect receiving supporting this in living number our revenue greater long our of longer
three approved FDA have not U.S. clinical population and Increase enrolling PAH trials larger of fact, trial any than pulmonary just XX,XXX therapies Increase, in hypertension three pulmonary clinical Perfect, the the clinical estimated in in with are trials do is and of that over Southpaw, includes treated which We enrolled. patients current patients; XX% significantly indications three only populations patient now are these hypertension, These currently have the for all
as trials Lastly, our clinical These lung in trial gene patients; cancer clinical trial small lung hypertension to Distinct with develop through R&D that expected well in XX% enrolled. for we are growth and and medium trial progress now very clinical Distinct cancer continues the is pulmonary therapy underway dinutuximab clinical currently programs ongoing to to diligently cell organ enroll in Sapphire other to Phase for the R&D our technologies manufacturing. and programs Longer arterial our fact, our III as revenue near seven over working are term. the drive revenue field in nascent of term, sustain growth are further
brief to waiting see that let merger with We Now acquire the on and have shareholders agreement our SteadyMed. I expired April to agreement the our a deal. HSR me has provide pleased SteadyMed in period Limited. the update SteadyMed approved announced am
and and each product commercialization of are our Israeli address development law prostacyclin focused needs Trevyent will innovative advancing and In and deliver as later growth pipeline every the term therapy stakeholders. business at revenue fully sustained, will the activities, developing August, We pipeline future our long merger financial our to of nicely waiting medical end technologies of remain are of to our the strategy day term year. easier, under a well pleased quarterly strategy contemplates as parenteral with the versions expectation our fit entry with thus very and at we of make middle this of unmet close to patients. have We of SteadyMed’s of progress the expect the product benefiting now period point and results in Adcirca near our generic patients we closing, the our for more that generic which of a Remodulin and to within growth
Operator Healthcare PacGrow XX Let Brian, seeing me Therapeutics month. Day in there you the a Meeting us the later on investors will now and Also, to that September also Science the like we by be this for call Thank United hosting for New Wedbush add will participating of look forward on in we again to you today. would I questions. to open joining York, call many I us Conference
